Genprex shares surge 17.79% intraday on positive preclinical data for REQORSA from cancer conference.

Genprex, Inc. (GNPX) surged 17.79% during intraday trading, driven by renewed investor interest in its gene therapy pipeline and market speculation. The stock gained momentum following discussions on social media platforms highlighting positive preclinical data for its lead candidate, REQORSA, presented at a major cancer therapeutics conference. Analysts and investors noted the low float and high borrow rate as catalysts for rapid price movements, while anticipation for upcoming financial results and business updates further fueled optimism. Institutional activity also supported the rally, with Susquehanna and UBS increasing holdings in Q2 2025. The surge aligns with broader market enthusiasm for biotech innovation and short-term speculative positioning, despite mixed hedge fund activity in recent quarters.